TerminatedPhase 3NCT01287221
Study of Rifampicin in Multiple System Atrophy
Studying Multiple system atrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Phillip Low
- Principal Investigator
- Phillip A Low, MDMayo Clinic
- Intervention
- Rifampicin(drug)
- Enrollment
- 100 target
- Eligibility
- 30-80 years · All sexes
- Timeline
- 2011 – 2013
Study locations (10)
- UCLA Medical Center, Los Angeles, California, United States
- University of California, San Diego, San Diego, California, United States
- Mayo Clinic, Jacksonville, Florida, United States
- University of South Florida, Tampa, Florida, United States
- Harvard Medical School, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- New York University, New York, New York, United States
- Vanderbilt University, Nashville, Tennessee, United States
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS) · Vanderbilt University · Rare Disease Research Network Autonomic Consortium
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01287221 on ClinicalTrials.govOther trials for Multiple system atrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07446894MSA-01 in Multiple System AtrophyTokyo University
- RECRUITINGPHASE2NCT07197866An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System AtrophyTeva Branded Pharmaceutical Products R&D LLC
- ENROLLING BY INVITATIONNCT07081841AB-1005 Long-Term Follow-up StudyAskBio Inc
- RECRUITINGPHASE1, PHASE2NCT06831500Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease.Julien Bally
- RECRUITINGEARLY PHASE1NCT06765733The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System AtrophyBeijing Tiantan Hospital
- RECRUITINGPHASE2NCT06868628A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)Tiziana Life Sciences LTD
- RECRUITINGNCT07353463Shanghai Clinical Cohort - Parkinson's Disease (Reserve)Ruijin Hospital
- RECRUITINGEARLY PHASE1NCT06891703[18F]ACI-15916 PET in α-synucleinopathiesAC Immune SA